Status:
UNKNOWN
A Phase 1 Clinical Trial to Explore Systemic Exposure of CTO0101 Eye Drops, Safety and Local Tolerability in Healthy Adults
Lead Sponsor:
Taejoon Pharmaceutical Co., Ltd.
Conditions:
Healthy
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic characteristic of CTO0101
Eligibility Criteria
Inclusion
- Healthy male and female volunteers
- Written informed consent to participate in the trial
Exclusion
- Those who have a history of ophthalmic diseases and surgery within 5 years
- Smokers with an average daily smoking amount exceeding 10 cigarettes
Key Trial Info
Start Date :
October 5 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 5 2022
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT05262179
Start Date
October 5 2021
End Date
July 5 2022
Last Update
March 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taejoon Pharmaceutical Co., Ltd.
Seoul, South Korea